The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities장기 요양 시설에서 COVID-19 발병을 이해하는 데 바이러스 유전체학의 역할Review Published on 2022-02-012022-09-11 Journal: The Lancet. Microbe [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료기술, [키워드] Analysis Care Cluster Community COVID-19 COVID-19 outbreak Epidemiology event followed by genome sequence genomic Genomics individual infection control involved Lineage Local Long-term care Measures mortality rate Multiple studies persistence predominant robust SARS-CoV-2 genomes Sequencing sequencing data Spread Transmission [DOI] 10.1016/S2666-5247(21)00208-1 PMC 바로가기 [Article Type] Review
Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodiesSARS-CoV-2 RBD 스파이크 단백질과 다양한 특정 단일클론항체 간의 분자 상호작용 규명Article Published on 2022-02-012022-09-12 Journal: Biochimie [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accelerated Accelerated molecular dynamics ACE2 ACE2 receptor approach cell receptor conformation Conformational study conformations COVID-19 disease CR3022 determine drugs epitope identify increase Interaction knowledge mAb mAbs molecular molecular interaction monoclonal antibody physiological conditions predominant protein-protein interaction RBD Result S protein S309 Salt Bridge SARS-CoV-2 spike glycoprotein Spike protein the RBD the receptor-binding domain the SARS-CoV-2 therapeutic therapeutic option treat Vaccine virus [DOI] 10.1016/j.biochi.2021.10.013 PMC 바로가기 [Article Type] Article
CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta VariantBrief Report Published on 2022-02-012022-10-28 Journal: Viruses [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS, [키워드] antibodies antibody ChAdOx1 convalescence convalescent individual CoronaVac COVID-19 Delta delta variant Efficacy Efficiency elicited evaluated expected Gamma Gamma variant highlighting individual infected individuals Lineage neutralization Neutralizing new SARS-CoV-2 predominant public health raising reduced reduction in replacing SARS-CoV-2 sensitivity spread to the SARS-CoV-2 vaccination variant [DOI] 10.3390/v14020305 PMC 바로가기 [Article Type] Brief Report
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant델타 변이체의 출현으로 심각한 COVID-19를 예방하는 모노클로날 항체의 효과Article Published on 2022-02-012022-09-11 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI adjusted Alpha Anti-spike anti-spike monoclonal antibodies anti-spike monoclonal antibody approved Beta Beta variant beta variants can not Charlson Comorbidity Index clinical setting Cohort Comorbidity COVID-19 death Delta delta variant effective strategy Effectiveness Efficacy emergence epoch excluded higher odd higher odds Hospitalization infused maintain monoclonal monoclonal antibodies monoclonal antibody Odds ratio outcome Patient predominant Preventing question retrospective cohort severe disease Severe infection the SARS-CoV-2 Treatment variant virulent [DOI] 10.1016/j.mayocp.2021.12.002 PMC 바로가기 [Article Type] Article
SARS-CoV-2 in Egypt: epidemiology, clinical characterization and bioinformatics analysisResearch Article Published on 2022-01-312022-10-31 Journal: Heliyon [Category] COVID-19, [키워드] age average B.1 Bioinformatics analysis C-reactive protein caused clade clinical Clinical data clinical symptom collected conducted coronavirus COVID-19 CT finding D-dimer dry cough epidemiological Epidemiology Evolution feature Fever GenBank Genome genomic sequencing Haemoglobin Haplotype haplotypes identity Illumina Infectious disease isolate Laboratory Lineage lymphocytopenia male Mutation NCBI pandemic participant patients Pneumonia predominant reported resulting rRT-PCR SARS-CoV-2 SARS-CoV-2 variant sequence sequenced Serum ferritin Spread strain submitted suspected patient Swab System unique variant virus was performed Whole genome sequencing Wuhan-Hu-1 [DOI] 10.1016/j.heliyon.2022.e08864 PMC 바로가기 [Article Type] Research Article
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial보조제 서브유닛 단백질 COVID-19 백신, SCB-2019의 효능: 2상 및 3상 다기관, 이중 맹검, 무작위 배정, 위약 대조 시험Clinical Trial Published on 2022-01-292022-09-11 Journal: Lancet (London, England) [Category] 변종, 임상, [키워드] 1:1 95% CI alum assigned baseline Belgium biopharmaceutical Brazil caused chloride circulating Clover Coalition country COVID 19 COVID-19 COVID-19 case COVID-19 vaccine CpG Cutoff dose doses double-blind effective vaccine Effective vaccines Efficacy efficacy analysis elicited Endpoint enrolled EudraCT exclusion FIVE follow-up period groups Health health condition injection injection site pain intramuscular dose Local median Mild-to-moderate moderate-to-severe COVID-19 MOST multicentre notable Older pandemic participant per-protocol per-protocol population Phase 2 Placebo placebo recipients placebo-controlled trial predominant primary endpoints Protein provide randomisation randomised Randomly receive Registered RT-PCR Safe SAR-CoV-2 SARS CoV SARS-CoV-2 SCB-2019 second dose seronegative participant Seropositivity severe COVID-19 severity Sodium chloride South Africa subset subunit systemic adverse event systemic adverse events Vaccine vaccine efficacy vaccinee vaccinees variant virus virus variants viruses was done [DOI] 10.1016/S0140-6736(22)00055-1 PMC 바로가기 [Article Type] Clinical Trial
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods – United States, December 2020-January 2022이전 SARS-CoV-2 높은 전염 기간과 비교하여 초기 오미크론 변이 기간 동안의 질병 심각도 및 의료 이용 추세 - 미국, 2020년 12월-2022년 1월Comparative Study Published on 2022-01-282022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] 변종, [키워드] addition Admission Admissions appear average B.1.1.529 B.1.617.2 Care cause CDC circulating variant clinically Coverage COVID-19 COVID-19 disease COVID-19 disease severity COVID-19 patient COVID-19 patients Critical database death Delta died disease severity emergency department examined Health Health care Health care system health care systems Health Care Utilization highest hospital Hospital admission Hospital admissions Hospitalization hospitalizations hospitalized COVID-19 patient hospitalized COVID-19 patients hospitals ICU Immunity IMV infections intensive care intensive care unit Invasive mechanical ventilation less Local maximum moving average National nine omicron Omicron variant percentage percentages Period predominant reduce reported SARS-CoV-2 sequenced Severity of disease shown specimen Spread Surveillance the mean the United State The United States Transmission trend United States utilization vaccination variant variant of SARS-CoV-2 virulence virulent virus Volume Winter [DOI] 10.15585/mmwr.mm7104e4 PMC 바로가기 [Article Type] Comparative Study
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis – California and New York, May-November 2021COVID-19 예방 접종 상태 및 이전 COVID-19 진단에 따른 COVID-19 사례 및 입원 - 캘리포니아 및 뉴욕, 2021년 5월-11월Article Published on 2022-01-282022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] 변종, [키워드] accounted analyzed booster dose booster doses both group both groups cause changed Cohort cohorts completion COVID-19 COVID-19 case COVID-19 diagnosis COVID-19 incidence COVID-19 vaccination death deaths declined delta variant diagnoses Diagnosis diagnosis of COVID-19 Duration of infection eligible Epidemic Epidemiology highest Hospitalization hospitalizations immune evasion Immunity immunization Immunologic Infection infection with SARS-CoV-2 isolates laboratory-confirmed magnitude New New York occurred omicron outcome predominant Prevent previous diagnosis PROTECT public health recommendation Reinfection SARS-COV-2 infection SARS-CoV-2 infections sequenced status study period Surveillance the SARS-CoV-2 three groups vaccination vaccine dose vaccine doses Vaccine-induced immunity variants virus with COVID-19 [DOI] 10.15585/mmwr.mm7104e1 PMC 바로가기 [Article Type] Article
An Early Th1 Response Is a Key Factor for a Favorable COVID-19 EvolutionArticle Published on 2022-01-272022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] 95% CI acquisition activated acute phase Analysis analyzed anti-SARS-CoV-2 antibody AUC Cell mediated immunity Comorbidities Course COVID-19 COVID-19 patient Critical Diagnosis disease Diseases evaluate event Evolution Factor flow cytometry form four group healthy controls Hospitalization identify imbalanced immune response immune response Immunity immunological independent Infection inflammatory parameters less pathology Patient predominant progression protective factor Randomized response robust SARS-CoV-2 infected individual SARS-CoV2 severe COVID-19 patient severity specificity subset Symptomatic patients T helper T-cell T-cell subsets T-cells Th1 Th1 immunity Th1 response Th17 Th2 the disease the SARS-CoV-2 [DOI] 10.3390/biomedicines10020296 PMC 바로가기 [Article Type] Article
Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military PersonnelMedicine Published on 2022-01-272022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] analyzed approved characterization characterized circulating clinical sample Cohort collected complicate COVID-19 pandemic Delta delta variant Effectiveness effort emerging SARS-CoV-2 variants genomic Healthcare system imperative increase in Increasing Isolation MONITOR nasal swab nasal swabs Next-generation sequencing other variant other variants PCR positive sample predominant provide qRT-PCR quantification Quantitative real time SARS-CoV-2 SARS-CoV-2 isolate SARS-CoV-2 variant Sequencing study population subset Surveillance unique United State vaccine breakthrough infection Vaccines variant variants viable virus viral shedding Virological virus [DOI] 10.3389/fmed.2021.836658 PMC 바로가기 [Article Type] Medicine